New cell therapy tested for Tough-to-Treat cancers
Disease control
Not yet recruiting
This early study is testing a new cell therapy called NK510 for people with advanced stomach or colorectal cancer that has come back or stopped responding to standard treatments. The study will give NK510 through an IV or directly into the abdomen to see if it is safe and if it h…
Phase: EARLY_PHASE1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC